Skip to main content
Top
Published in: Breast Cancer Research and Treatment 1/2012

01-01-2012 | Brief Report

Resolution of extensive leptomeningeal metastasis and clinical spinal cord compression from breast cancer using weekly docetaxel chemotherapy

Authors: Bethany Wilson, Christy Sapp, Ghadeer Abdeen, Atheel Kamona, Suleiman Massarweh

Published in: Breast Cancer Research and Treatment | Issue 1/2012

Login to get access

Abstract

Metastatic breast cancer to the leptomeninges is a late event in the disease course and is associated with significant morbidity and a grave prognosis. Treatment typically involves direct intrathecal injection of chemotherapy into the cerebrospinal fluid compartment since systemic chemotherapy penetrates poorly to the central nervous system. Here we report an interesting clinical observation involving a patient presenting with leptomeningeal spread of breast cancer causing extensive spinal cord compression with obliteration of the subarachnoid space, thus precluding the use of direct intrathecal chemotherapy. We administered systemic chemotherapy using weekly docetaxel with complete radiographic resolution of her disease and recovery from clinical spinal cord compression. While this is a single clinical observation, weekly administration of docetaxel in this circumstance may have been associated with improved drug “escape” into the central nervous system and better antitumor effect. Because leptomeningeal disease is typically a late event in metastatic breast cancer, resistance to therapeutic intervention may reflect intrinsically resistant disease in the setting of extensive prior therapy rather than a routine problem with systemic drug delivery to the CNS. Studying patterns of disease relapse in patients who had received adjuvant weekly taxanes may provide insights into this hypothesis.
Literature
2.
go back to reference Boogerd W, Dorresteijn LD, van Der Sande JJ, de Gast GC, Bruning PF (2000) Response of leptomeningeal metastases from breast cancer to hormonal therapy. Neurology 55:117–119PubMed Boogerd W, Dorresteijn LD, van Der Sande JJ, de Gast GC, Bruning PF (2000) Response of leptomeningeal metastases from breast cancer to hormonal therapy. Neurology 55:117–119PubMed
3.
go back to reference Chamberlain MC (2001) Response of leptomeningeal metastases from breast cancer to hormonal therapy. Neurology 56:425–426PubMed Chamberlain MC (2001) Response of leptomeningeal metastases from breast cancer to hormonal therapy. Neurology 56:425–426PubMed
4.
go back to reference Ozdogan M, Samur M, Bozcuk HS, Sagtas E, Yildiz M, Artac M, Savas B (2003) Durable remission of leptomeningeal metastasis of breast cancer with letrozole: a case report and implications of biomarkers on treatment selection. Jpn J Clin Oncol 33:229–231. doi:10.1093/jjco/hyg046 PubMedCrossRef Ozdogan M, Samur M, Bozcuk HS, Sagtas E, Yildiz M, Artac M, Savas B (2003) Durable remission of leptomeningeal metastasis of breast cancer with letrozole: a case report and implications of biomarkers on treatment selection. Jpn J Clin Oncol 33:229–231. doi:10.​1093/​jjco/​hyg046 PubMedCrossRef
5.
go back to reference Sanna G, Franceschelli L, Rotmensz N, Botteri E, Adamoli L, Marenghi C, Munzone E, Cossu Rocca M, Verri E, Minchella I, Medici M, Catania C, Magni E, Goldhirsch A, Nole F (2007) Brain metastases in patients with advanced breast cancer. Anticancer Res 27:2865–2869PubMed Sanna G, Franceschelli L, Rotmensz N, Botteri E, Adamoli L, Marenghi C, Munzone E, Cossu Rocca M, Verri E, Minchella I, Medici M, Catania C, Magni E, Goldhirsch A, Nole F (2007) Brain metastases in patients with advanced breast cancer. Anticancer Res 27:2865–2869PubMed
6.
go back to reference Crivellari D, Pagani O, Veronesi A, Lombardi D, Nole F, Thrlimann B, Hess D, Borner M, Bauer J, Martinelli G, Graffeo R, Sessa C, Goldhirsch A, International Breast Cancer Study G (2001) High incidence of central nervous system involvement in patients with metastatic or locally advanced breast cancer treated with epirubicin and docetaxel. Ann Oncol 12:353–356PubMedCrossRef Crivellari D, Pagani O, Veronesi A, Lombardi D, Nole F, Thrlimann B, Hess D, Borner M, Bauer J, Martinelli G, Graffeo R, Sessa C, Goldhirsch A, International Breast Cancer Study G (2001) High incidence of central nervous system involvement in patients with metastatic or locally advanced breast cancer treated with epirubicin and docetaxel. Ann Oncol 12:353–356PubMedCrossRef
7.
go back to reference Freilich RJ, Seidman AD, DeAngelis LM (1995) Central nervous system progression of metastatic breast cancer in patients treated with paclitaxel. Cancer 76:232–236PubMedCrossRef Freilich RJ, Seidman AD, DeAngelis LM (1995) Central nervous system progression of metastatic breast cancer in patients treated with paclitaxel. Cancer 76:232–236PubMedCrossRef
8.
go back to reference Kosmas C, Malamos NA, Tsavaris NB, Stamataki M, Gregoriou A, Rokana S, Vartholomeou M, Antonopoulos MJ (2002) Isolated leptomeningeal carcinomatosis (carcinomatous meningitis) after taxane-induced major remission in patients with advanced breast cancer. Oncology 63:6–15PubMedCrossRef Kosmas C, Malamos NA, Tsavaris NB, Stamataki M, Gregoriou A, Rokana S, Vartholomeou M, Antonopoulos MJ (2002) Isolated leptomeningeal carcinomatosis (carcinomatous meningitis) after taxane-induced major remission in patients with advanced breast cancer. Oncology 63:6–15PubMedCrossRef
9.
go back to reference Kosmas C, Malamos NA, Tsavaris NB, Stamataki M, Stefanou S, Gregoriou A, Rokana S, Vartholomeou M, Antonopoulos MJ (2002) Leptomeningeal carcinomatosis after major remission to taxane-based front-line therapy in patients with advanced breast cancer. J Neurooncol 56:265–273PubMedCrossRef Kosmas C, Malamos NA, Tsavaris NB, Stamataki M, Stefanou S, Gregoriou A, Rokana S, Vartholomeou M, Antonopoulos MJ (2002) Leptomeningeal carcinomatosis after major remission to taxane-based front-line therapy in patients with advanced breast cancer. J Neurooncol 56:265–273PubMedCrossRef
10.
go back to reference Tham YL, Hinckley L, Teh BS, Elledge R (2006) Long-term clinical response in leptomeningeal metastases from breast cancer treated with capecitabine monotherapy: a case report. Clin Breast Cancer 7:164–166PubMedCrossRef Tham YL, Hinckley L, Teh BS, Elledge R (2006) Long-term clinical response in leptomeningeal metastases from breast cancer treated with capecitabine monotherapy: a case report. Clin Breast Cancer 7:164–166PubMedCrossRef
11.
go back to reference Ekenel M, Hormigo AM, Peak S, Deangelis LM, Abrey LE (2007) Capecitabine therapy of central nervous system metastases from breast cancer. J Neurooncol 85:223–227PubMedCrossRef Ekenel M, Hormigo AM, Peak S, Deangelis LM, Abrey LE (2007) Capecitabine therapy of central nervous system metastases from breast cancer. J Neurooncol 85:223–227PubMedCrossRef
13.
go back to reference Ten Tije AJ, Loos WJ, Zhao M, Baker SD, Enting RH, van der Meulen H, Verweij J, Sparreboom A (2004) Limited cerebrospinal fluid penetration of docetaxel. Anticancer Drugs 15:715–718PubMedCrossRef Ten Tije AJ, Loos WJ, Zhao M, Baker SD, Enting RH, van der Meulen H, Verweij J, Sparreboom A (2004) Limited cerebrospinal fluid penetration of docetaxel. Anticancer Drugs 15:715–718PubMedCrossRef
14.
go back to reference Sparano JA, Wang M, Martino S, Jones V, Perez EA, Saphner T, Wolff AC, Sledge GW Jr, Wood WC, Davidson NE (2008) Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 358:1663–1671. doi:10.1056/NEJMoa0707056 PubMedCrossRef Sparano JA, Wang M, Martino S, Jones V, Perez EA, Saphner T, Wolff AC, Sledge GW Jr, Wood WC, Davidson NE (2008) Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 358:1663–1671. doi:10.​1056/​NEJMoa0707056 PubMedCrossRef
Metadata
Title
Resolution of extensive leptomeningeal metastasis and clinical spinal cord compression from breast cancer using weekly docetaxel chemotherapy
Authors
Bethany Wilson
Christy Sapp
Ghadeer Abdeen
Atheel Kamona
Suleiman Massarweh
Publication date
01-01-2012
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 1/2012
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-011-1825-3

Other articles of this Issue 1/2012

Breast Cancer Research and Treatment 1/2012 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine